Review Article

Published: Nov 12, 2026 | DOI: 10.24911/amem.15-3203

Dexmedetomidine for the treatment of established delirium in critically ill adults: a comparator-stratified systematic review and meta analysis


Authors: Raed Abdulkhaliq Alzahrani , Reman Mohammed Alghamdi , Mohammed Hassan Alzahrani , Abdulhakeem Ali Alghamdi , Meshref Sultan Alghamdi , Rawan Mohammed Alzahrani , Lama Mohammed Alzahrani , Shahad Abdulrahman Alzahrani , Sultan Meshref Alghamdi


Abstract

Dexmedetomidine is widely used to treat delirium already present in critically ill adults, but the evidence for that use has not been synthesised since 2020 and has never been separated by comparator drug. We searched four databases from inception to March 2026, with trial registers and reference mining, for randomised and non-randomised studies of adults with instrument-confirmed delirium comparing dexmedetomidine with placebo, an antipsychotic or propofol. Two reviewers screened and extracted independently, rated risk of bias by outcome using RoB 2 and ROBINS-I, and rated certainty using GRADE. Comparator strata were never pooled together. Eight studies were included: six randomised trials with 532 participants and two non-randomised studies with 395. Neither co-primary outcome could be pooled, because six trials measured delirium duration as four different quantities in two units and agitation duration was quantified in one trial only. Three pooled estimates were possible, each from two trials. Rescue-medication use against placebo gave a risk ratio of 0.69 (Hartung-Knapp 95% CI 0.21 to 2.26) and intensive care length of stay a mean difference of -0.56 days (-12.99 to 11.88); at two trials the Hartung-Knapp critical value is 12.7, so no pooled estimate excluded the null. Mortality at 90 days was higher with dexmedetomidine than olanzapine (33 of 94 versus 19 of 94; risk ratio 1.74, 95% CI 1.07 to 2.83). Certainty was low or very low throughout. The randomised evidence is too sparse and too fragmented by outcome definition to support a pooled estimate for either co-primary outcome.


Keywords: Delirium, dexmedetomidine, critical illness, intensive care units, systematic review, meta-analysis.



Pubmed Style

Raed Abdulkhaliq Alzahrani, Reman Mohammed Alghamdi, Mohammed Hassan Alzahrani, Abdulhakeem Ali Alghamdi, Meshref Sultan Alghamdi, Rawan Mohammed Alzahrani, Lama Mohammed Alzahrani, Shahad Abdulrahman Alzahrani, Sultan Meshref Alghamdi. Dexmedetomidine for the treatment of established delirium in critically ill adults: a comparator-stratified systematic review and meta analysis. AMEM. 2026; 12 (November 2026): -. doi:10.24911/amem.15-3203

Publication History

Received: September 30, 2026

Accepted: October 23, 2026

Published: November 12, 2026


Authors

Raed Abdulkhaliq Alzahrani

Medical Intern, Faculty of Medicine, Al-Baha University, AlBaha, Saudi Arabia.

Reman Mohammed Alghamdi

Medical Intern, Faculty of Medicine, Al-Baha University, AlBaha, Saudi Arabia.

Mohammed Hassan Alzahrani

Medical Intern, Faculty of Medicine, Al-Baha University, AlBaha, Saudi Arabia.

Abdulhakeem Ali Alghamdi

Medical Intern, Faculty of Medicine, Al-Baha University, AlBaha, Saudi Arabia.

Meshref Sultan Alghamdi

Medical Student, Faculty of Medicine, Al-Baha University, Al-Baha, Saudi Arabia.

Rawan Mohammed Alzahrani

Medical Intern, Faculty of Medicine, Al-Baha University, AlBaha, Saudi Arabia.

Lama Mohammed Alzahrani

Medical Student, Faculty of Medicine, Al-Baha University, Al-Baha, Saudi Arabia.

Shahad Abdulrahman Alzahrani

Medical Student, Faculty of Medicine, Al-Baha University, Al-Baha, Saudi Arabia.

Sultan Meshref Alghamdi

King Fahad Hospital, Al-Baha Health Cluster, Al-Baha, Saudi Arabia.